Boehringer Ingelheim flies the white flag as last holdout surrenders in war over a $20B AbbVie gold mine
After battling it out in the courts as the last big holdout in the fight over AbbVie’s Humira patents, Boehringer Ingelheim has dropped neatly into the lineup for a 2023 biosimilar rollout.
The German outfit will now introduce its biosimilar on July 1, 2023, giving AbbVie a complete victory in its quest to maintain complete control of the world’s biggest drug franchise for more than 4 years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.